<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="133000">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02154178</url>
  </required_header>
  <id_info>
    <org_study_id>2013 A00756 39</org_study_id>
    <nct_id>NCT02154178</nct_id>
  </id_info>
  <brief_title>Fungal Biomarkers to Reduce Duration of Empirical Antifungal Therapy: a Randomized Comparative Study (STAFE)</brief_title>
  <acronym>STAFE</acronym>
  <official_title>Fungal Biomarkers to Reduce Duration of Empirical Antifungal Therapy: a Randomized Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesized that the use of biomarkers of invasive fungal infections
      would increase the percentage of early discontinuation of empirical antifungal therapy and
      thus reduce the duration of treatment in ICU patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of empirical/preemptive anti fungal treatment will be based in the intervention
      group on biomarker results.

      Biomarkers of fungal disease will performed before starting anti fungal treatment and at day
      4.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>percentage of early discontinuation of empiric antifungal therapy</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Early discontinuation is defined as discontinuation of anti fungal treatment before the 7th day after the start of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mortality in ICU</measure>
    <time_frame>28 days after ICU admission</time_frame>
    <safety_issue>No</safety_issue>
    <description>death during the 28 days following ICU admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of mechanical ventilation and ICU stay</measure>
    <time_frame>28 days after ICU admission</time_frame>
    <safety_issue>No</safety_issue>
    <description>mechanical ventilation duration during the 28 days following ICU admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fungal colonization / infection after antifungal therapy, with or without resistant strains</measure>
    <time_frame>28 days after ICU admission</time_frame>
    <safety_issue>No</safety_issue>
    <description>Any fungal colonization or infection diagnosed during the 28 days following ICU admission</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Fungal Infection</condition>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Biomarker group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention group, in which the duration of empirical antifungal therapy will be based on the results of biomarkers.
Biomarker group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group, in which the duration of empirical antifungal therapy will be based on international recommendations (14 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biomarker group</intervention_name>
    <description>use of invasive fungal disease biomarkers (β-1,3-glucan, mannan/anti-mannan antibodies)</description>
    <arm_group_label>Biomarker group</arm_group_label>
    <other_name>intervention group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; or = 18 years

          -  Patients requiring empiric antifungal therapy the first time in the ICU

          -  Predictable duration of hospitalization in the ICU ≥ 6 days

        Exclusion Criteria:

          -  Neutropenia (WBC &lt;1000 or neutrophils &lt;500/mm3)

          -  Immunosuppressive therapy (chemotherapy within 3 months prior to the ICU admission,
             solid organ graft under immunosuppressive therapy)

          -  invasive fungal infection documented in the three previous months

          -  Antifungal treatment in the three previous months

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saad Nseir, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univ Hosp of Lille, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Saad nseir, MD</last_name>
    <phone>0033320444084</phone>
    <email>saadalla.nseir@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>ICU, Salengro Hospital, University Hospital of Lille</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59035</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saad Nseir, MD, PhD</last_name>
      <phone>0033320444084</phone>
      <email>s-nseir@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Saad Nseir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 29, 2014</lastchanged_date>
  <firstreceived_date>May 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Lille</investigator_affiliation>
    <investigator_full_name>Saad NSEIR</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>empiric antifungal therapy</keyword>
  <keyword>biomarkers</keyword>
  <keyword>invasive fungal infection</keyword>
  <keyword>Candida</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Mycoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antifungal Agents</mesh_term>
    <mesh_term>Clotrimazole</mesh_term>
    <mesh_term>Miconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
